S-4993-119
Read twice and referred to the Committee on Veterans' Affairs.
Sponsored by Jerry Moran (R-KS)
What it does
This bill would direct the Secretary of Veterans Affairs to establish a precision oncology program for prostate cancer within the VA, designating 28 specific VA medical facilities as provisional centers of excellence. Each center would be required to offer genetic sequencing, clinical trials, telemedicine tumor boards, and travel support for eligible veterans. The bill authorizes $15.5 million per year for fiscal years 2027 through 2029 and requires annual reports to Congress on program performance.
Who benefits
Veterans diagnosed with prostate cancer, particularly those with advanced or metastatic disease who would gain access to genetic sequencing and biomarker-specific clinical trials. Veterans in all 18 VA Integrated Service Networks, since at least one center must operate in each. Early-career VA medical researchers who would receive mentorship through the program. Academic and pharmaceutical industry partners who would collaborate on clinical trials. The Seattle VA Medical Center, which would host the Program Leadership team and gain institutional prominence.
Who is hurt
VA medical facilities not designated as centers of excellence, which may see resources or specialized staff drawn toward the 28 designated sites. Veterans with other cancers or serious conditions who compete for VA staffing and funding resources. Taxpayers who bear the cost of the $46.5 million three-year authorization. Private oncology providers and cancer centers that may lose veteran patients to the VA network. VA staff at designated centers who may face increased workload demands from the program's mandatory activities and reporting requirements.
Supporters argue
Supporters argue that prostate cancer is the most common non-skin cancer among male veterans, and that precision oncology — matching treatment to a patient's specific genetic mutations — has demonstrated significantly improved outcomes in advanced cases compared to standard care. They contend that the VA's large, integrated patient population makes it uniquely positioned to build a national research network, and that centralizing expertise at 28 geographically distributed centers would expand access to cutting-edge care for veterans who might otherwise lack it.
Opponents argue
Opponents argue that the bill mandates highly specific operational requirements — including minimum staffing compositions, in-person meeting schedules, and a uniform sequencing platform — that may be impractical given the VA's well-documented staffing shortages and could divert limited oncology specialists away from general cancer care for veterans. They contend that the $15.5 million annual authorization may be insufficient to fund the required staffing and infrastructure at 28 centers, potentially creating an underfunded mandate that produces uneven care quality across sites.